Investment Rating - The industry rating is "Recommended" [3] Core Insights - The report highlights the strengthening of pork prices as the breeding stock decreases to 35.61 million heads by the end of December, indicating a bullish trend in the market [1][2] - The report emphasizes the importance of the seed industry revitalization action, which has made significant progress in enhancing seed security and promoting domestic seed usage [1][12] - The commercialization of genetically modified crops is expected to accelerate, contributing to higher self-sufficiency rates in key varieties [1][12] Summary by Sections Planting Industry - The Ministry of Agriculture and Rural Affairs has reported progress in the seed industry revitalization action, with a focus on policy support, funding, and institutional guarantees [1][12] - Key companies recommended for investment include Beidahuang and Suqian Agricultural Development, as well as leading seed companies like Dabeinong and Longping High-Tech [1][12] Pig Farming - The average price of live pigs is reported at 12.99 CNY/kg, with a week-on-week increase of 2.27% [2][13] - The breeding stock of sows is at 39.61 million heads, showing a year-on-year decrease of 2.9% [2][13] - Recommended companies in the pig farming sector include Lihua Co., Muyuan Foods, and Shuanghui Development [5][13] Feed and Veterinary - The average price of pig feed is 2.65 CNY/kg, reflecting a week-on-week increase of 0.38% [52] - Companies in the feed sector such as Haida Group and veterinary companies like Jinhai Biological and Zhongmu Co. are expected to benefit [5][13]

Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

证券日报网讯 1月21日，金河生物发布公告称，近日，公司对募集资金专户进行了销户。 （文章来源：证券日报） ...

Core Viewpoint - The animal health sector experienced a decline of 0.65% on January 21, with Huisheng Biological leading the drop. The Shanghai Composite Index rose by 0.08%, while the Shenzhen Component Index increased by 0.7 [1] Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Shunlian Biological up by 4.20% and Huisheng Biological down by 6.19% [1][2] - The trading volume for Huisheng Biological was 419,900 shares, with a transaction value of 1.192 billion yuan, indicating significant market activity despite the decline [2] Group 2: Capital Flow - The animal health sector saw a net inflow of 9.6935 million yuan from institutional investors, while retail investors experienced a net outflow of 73.8174 million yuan, suggesting a shift in investor sentiment [2][3] - Among individual stocks, Xianfeng Holdings had a net inflow of 15.1182 million yuan from institutional investors, while Huisheng Biological saw a net outflow of 42.2249 million yuan from retail investors [3]

证券代码：002688 证券简称：金河生物 公告编号：2026-006 金河生物科技股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、募集资金基本情况 根据 2020 年 12 月 4 日中国证券监督管理委员会（以下简称"中国证监会"） 核发的《关于核准金河生物科技股份有限公司非公开发行股票的批复》（证监许 可[2020]3344 号）文核准，公司获准非公开发行 145,132,743 股，每股面值人 民币 1 元，发行价格为每股人民币 5.65 元，实际募集资金总额为 819,999,997.95 元，扣除不含税发行费用人民币 17,756,396.62 元后，实际募集资金净额为 802,243,601.33 元。公司以上募集资金已经信永中和会计师事务所（特殊普通 合伙）审验，并出具了 XYZH/2021XAAA50306 号《验资报告》予以确认。 | 序号 | 项目名称 | 项目总投资 | 拟使用募集资金 总额 | | --- | --- | --- | --- | | 1 | 动物疫苗生产基地建 ...

金河生物公告称，2021年公司非公开发行股票，实际募集资金净额8.02亿元。"生产工艺系统降耗增效 改造项目"已基本建设完成，公司对该募投项目结项，将节余募集资金232.77万元（含利息收入）永久 补充流动资金，募投项目未支付款项由自有资金支付。近日，公司注销该项目募集资金专户（开户行： 中国民生银行呼和浩特分行；账号：633142845），相关《募集资金三方监管协议》相应终止。 ...

Core Insights - The pet economy in China is rapidly expanding, with the market expected to exceed 811.4 billion yuan by 2025, and the urban pet population reaching 120 million [2][6]. Group 1: Industry Overview - The pet economy has evolved from mere companionship to a lifestyle, creating a vast ecosystem around the entire lifecycle of pets [5][6]. - The geographical distribution and specialization within the pet industry have developed into a national framework, with significant contributions from various regions [6][7]. Group 2: Regional Highlights - Liaoning Anshan is emerging as a major hub for pet breeding, supplying over 60% of the national pet dog and cat population, with an industry scale exceeding 10 billion yuan [18][19][20]. - Hebei and Shandong are recognized as the primary pet food production areas, with a projected 14% increase in pet food shipment volume by 2025 [30][31]. - The Yangtze River Delta is positioned as the "universe center" for pet supplies, leveraging its supply chain advantages and manufacturing capabilities [49][50]. Group 3: Emerging Trends - The pet vaccine sector is witnessing significant growth, with companies like Princely and Jinhe Bio reporting substantial revenue increases, indicating a burgeoning market for pet health products [78][86]. - The smart pet products market is projected to surpass 10.2 billion yuan, driven by advancements in AI and e-commerce integration [91][92]. - The "pet+" trend is gaining traction, with services like pet transportation and photography experiencing exponential growth, reflecting a shift towards emotional spending in pet ownership [106][108]. Group 4: Infrastructure and Services - Guangzhou Baiyun Airport has become the first pet-friendly airport in China, facilitating easier travel for pet owners [120][129]. - The development of pet-friendly cities and services is on the rise, enhancing the overall experience for pet owners and their pets [116][118].

Core Viewpoint - The company, Jinhe Biological, has stated its commitment to timely information disclosure in accordance with the Shenzhen Stock Exchange's listing rules and relevant laws and regulations [2] Group 1 - The company responded to investor inquiries on its interactive platform [2] - Jinhe Biological emphasized its adherence to legal requirements for information disclosure [2]

Market Overview - The animal health sector increased by 3.21% on January 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] Stock Performance - Huisheng Biological (300871) closed at 28.16, up 8.18% with a trading volume of 331,800 shares [1] - Zhongmu Co., Ltd. (600195) closed at 8.49, up 7.88% with a trading volume of 435,600 shares [1] - Other notable performers include: - Biological Co. (600201) at 18.28, up 3.80% [1] - Jinhai Biological (002688) at 6.45, up 3.53% [1] - Shunlian Biological (688098) at 9.91, up 3.23% [1] Capital Flow - The animal health sector saw a net inflow of 175 million yuan from institutional investors, while retail investors experienced a net outflow of 171 million yuan [2] - The main capital flow details include: - Huisheng Biological had a net outflow of 59.49 million yuan from institutional investors [3] - Biological Co. had a net inflow of 58.13 million yuan from institutional investors [3] - Jinhai Biological experienced a net inflow of 35.35 million yuan from institutional investors [3]